However, q-PCR data on the S100P, MAPK11, CX3CL1, and PRDM16 genes in an in vivo pancreatic cancer model all show significant downregulation following QN-302 treatment [10,148] (unpublished observations). This evidence concerns the gene S100P and familial pancreatic carcinoma.